UV-Induced Tolerance to a Contact Allergen Is Impaired in Polymorphic Light Eruption  by Koulu, Leena M. et al.
UV-Induced Tolerance to a Contact Allergen Is
Impaired in Polymorphic Light Eruption
Leena M. Koulu1, Jarmo K. Laihia1,2, Hanna-Helena Peltoniemi1 and Christer T. Janse´n1
Polymorphic light eruption (PLE) is a common skin disorder provoked by exposure to UVR. Its clinical symptoms
resemble those of a contact allergic reaction. PLE is generally considered a T-cell-mediated autoimmune
reaction toward a yet unidentified antigen formed in UVR-exposed skin. Predisposition to such an immune
reaction may result from aberrant epitope formation, increased immune reactivity to a universal epitope, or
diminished propensity to UVR-induced immunosuppression or to the induction of tolerance. In a study
comprising a total of 24 PLE patients and 24 healthy sex- and age-matched controls, we found that both groups
demonstrated similar immunosuppression of contact sensitization to diphenylcyclopropenone by earlier
exposure to solar-simulating UVR. However, only 1 out of 13 PLE patients (8%) versus 6 out of 11 controls (55%)
that had been immunosuppressed by UVR exhibited a state of immunotolerance toward the same allergen after
10–24 months (P¼ 0.023). We conclude that the impaired propensity to UVR-induced allergen-specific
immunotolerance may promote recurrent PLE.
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INTRODUCTION
As early as in 1942, Stephan Epstein introduced a theory of
polymorphic light eruption (PLE) being due to an immune
reaction toward an endogenous antigen formed in the skin by
exposure to UVR. He claimed the passive transfer of a
papular, delayed UVR sensitivity to healthy control persons
(Epstein, 1942). Subsequent investigations were not able to
repeat the passive transfer results (Shaffer et al., 1959), and
studies on the presence of the putative PLE-related cutaneous
antigen have yielded controversial results (Janse´n and
Helander, 1976; Gonzalez-Amaro et al., 1991). However,
the immune cell-mediated pathogenesis of PLE, similar to a
contact allergic reaction, still retains credibility (Stratigos
et al., 2002; de Gruijl, 2008; Wolf et al., 2009). Considering
the fact that 10% to around 20% of the adult population
in the Western countries acknowledge symptoms of
PLE (Morison and Stern, 1982; Ros and Wennersten, 1986;
Wolf et al., 1998; Rhodes et al., 2009), the putative
neoantigen(s) should be ubiquitous.
An individual could be predisposed to mount an immune
reaction toward an endogenous, UVR-induced antigen either
by enhanced cutaneous cell-mediated immunity or by
decreased UVR-induced downregulation of cell-mediated
immunity. Two recent studies found no indication of
increased contact sensitization, but rather decreased propen-
sity to UVR-induced inhibition of contact sensitization in PLE
patients in comparison with healthy control individuals
(Palmer and Friedmann, 2004; van de Pas et al., 2004).
However, the UVR dosages in these studies were related to
individual threshold doses for erythema, which on average
were slightly lower in the PLE patients (3.6 J cm2) than
in control subjects (4.8 J cm2) (van de Pas et al., 2004).
The patients were therefore exposed to slightly lower doses of
UVR. The same reservation applies to the study by Palmer
and Friedmann (2004). In this study, we wanted to compare
responses at identical absolute dose levels. Moreover, these
two earlier studies have only addressed the short-term
immunosuppression, whereas a potentially more important
parameter is the induction of long-term immune unrespon-
siveness, i.e., immunotolerance. Therefore, we compared PLE
patients and healthy control subjects not only with respect to
short-term UVR-induced immunosuppression, but also with
respect to tolerance induction. The results indicate that the
most prominent immune pathology in PLE is the diminished
propensity to be tolerized by UVR exposure.
RESULTS
Short-term UVR immunosuppression
In the UVR dose-finding experiment, the 2 standard
erythemal dose (SED) did not produce any suppression of
the induction of contact allergy to diphenylcyclopropenone
(DPCP) (0/7 subjects), the 4 SED suppressed the induction in
50% (2/4) of the subjects, whereas the 6 SED showed
suppression in almost all (11/12) subjects (Table 1). On the
basis of these results, the 4 SED UVR dose was used in a
subsequent study to reveal the possible difference in
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UVR-induced photoimmunosuppression in PLE patients and
healthy control subjects. This UVR dose suppressed
the induction of contact allergy in 63% (15/24) of the PLE
patients (Table 2a) and in 50% (12/24) of the healthy controls
(Table 2b). The difference was not statistically significant
(P¼0.56).
Long-term immunotolerance
To investigate whether the application of the contact allergen
on the previously UVR-exposed skin can induce tolerance,
15 PLE patients and 12 control volunteers, who had
demonstrated immunosuppression (no contact sensitization
after UVR exposure; Table 2a and b), were invited
to participate in a further study 10–24 months later.
Thirteen out of the 15 patients and 11 of the 12 control
individuals volunteered for the second DPCP sensitization
experiment. About one half (6/11) of the previously
UVR-immunosuppressed control subjects demonstrated
long-term immune tolerance, i.e., they did not show a
Table 1. Pilot UVR dose-finding study for
immunosuppression toward a sensitizing dose of
DPCP (40 lg) in healthy controls
Subject
UVR
dose PAR DPCP patch testing dose
Immuno-
suppression
6.4 lg 3.2 lg 1.6 lg 0.8 lg 0.4 lg
UV01 2 SED Yes ND +++ +++ ++ + No
UV02 2 SED Yes ND ND ND ND ND No
UV03 2 SED Yes ND + +?   No
UV04 2 SED Yes ND ++ + +?  No
UV05 2 SED Yes ND ++ + + +? No
UV06 2 SED Yes ND     No
UV07 2 SED Yes ND ND ++ + + No
UV08 4 SED Yes ND ++ + +  No
UV09 4 SED No      Yes
UV10 4 SED Yes      No
UV11 4 SED No      Yes
UV12 6 SED No      Yes
UV13 6 SED No      Yes
UV14 6 SED No      Yes
UV15 6 SED No      Yes
UV16 6 SED No      Yes
UV17 6 SED No      Yes
UV181 6 SED Yes ND     No
UV191 6 SED No      Yes
UV201 6 SED No      Yes
UV211 6 SED No      Yes
UV221 6 SED No      Yes
UV231 6 SED No      Yes
Abbreviations: DPCP, diphenylcyclopropenone; ND, not determined;
PAR, primary allergic response; SED, standard erythemal dose.
1Sensitized immediately after the irradiation.
Table 2. Effect of 4 SED of UVR on sensitization to
DPCP (40 lg) in (a) PLE patients and (b) healthy
controls
PAR DPCP patch testing dose
Immuno-
suppression
6.4 lg 3.2 lg 1.6 lg 0.8 lg 0.4 lg
(a) Patient
P01 f No      Yes
P02 f Yes ND +? -   No
P03 m Yes ND ++ ++ ++ ++ No
P04 f No      Yes
P05 f No      Yes
P06 f Yes ND ND + + + No
P07 m No      Yes
P08 f No      Yes
P09 f Yes      No
P10 f No      Yes
P11 f Yes ND     No
P12 m No      Yes
P13 f No      Yes
P14 m No      Yes
P15 f No      Yes
P16 f Yes ND     No
P17 f Yes +     No
P18 m Yes      No
P19 f Yes      No
P20 f No      Yes
P21 f No      Yes
P22 m No      Yes
P23 f No      Yes
P24 f No      Yes
(b) Control
C01 m Yes ND ++ + +  No
C02 m No      Yes
C03 m Yes      No
C04 m No      Yes
C05 m Yes ND     No
C06 f No      Yes
C07 f Yes      No
C08 f No      Yes
C09 m Yes ND ++ + + + No
C10 f Yes ND + +  - No
C11 m No      Yes
C12 f Yes ND     No
C13 f Yes ND ND ND ND ND No
C14 f Yes ND ND + + - No
Table 2 continued on the following page
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reaction upon resensitization, whereas only 8% (1/13) of the
PLE patients were tolerant to the allergen (Table 3a and b).
The results indicate that PLE patients have an impaired
ability to induce tolerance. The difference was statistically
significant for the whole groups (P¼ 0.023) and for the
female patients (n¼ 9) versus female control subjects (n¼ 8)
(P¼0.029), but not for the males (P40.05).
DISCUSSION
In contrast to the two earlier functional studies on UV
immunosuppression in PLE patients (Palmer and Friedmann,
2004; van de Pas et al., 2004), we used a fixed irradiation
dose chosen low enough (4 SED) to suppress only about
50% of the control subjects. No significant difference was
observed in the two groups in photoimmunosuppression of
contact allergy induction. We therefore conclude that
photoimmunosuppression induced by the same physical
dose of solar-simulating UVR is similar in PLE patients and
healthy control subjects.
To our knowledge it is previously unreported whether
the initially suppressed PLE patients have also lost their
immunological unresponsiveness to the allergen upon a later
attempted resensitization. In contrast to short-term immuno-
suppression, such antigen-specific unresponsiveness denotes
long-term, possibly lifelong, immunotolerance toward the
antigen. PLE patients who had been immunosuppressed by
UVR in the first phase of our study were therefore again
challenged with a sensitizing dose of DPCP 10–24 months
later. Only 8% of them failed to show resensitization; i.e.,
they were immunotolerant to the allergen. In contrast, 55% of
the healthy control subjects demonstrated immunotolerance.
This significant difference clearly indicates compro-
mised induction of immunotolerance in PLE. Interestingly,
Hammerberg et al. (1994) found that UVR-induced immu-
notolerance depends on CD11b-positive monocytes infiltrat-
ing the skin, and in later studies the skin of PLE patients were
found to display an aberrantly low influx of (commonly
CD11b-positive) neutrophils upon UVR challenge (Kolgen
et al., 2004), which tended to normalize after UV hardening
of the skin (Janssens et al., 2005).
Obviously, the induction of tolerance is a more demand-
ing process than the induction of short-term photoimmuno-
suppression in PLE. At the cellular level, it was found
that Langerhans cells appear reluctant to migrate from the
epidermis of PLE patients after UVR exposure, but this only
became manifest at large doses (Kolgen et al., 1999; Janssens
et al., 2005) and was not reproduced in other studies
(Wackernagel et al., 2004). The on average lower threshold
Table 2. Continued
PAR DPCP patch testing dose
Immuno-
suppression
6.4 lg 3.2 lg 1.6 lg 0.8 lg 0.4 lg
C15 f No      Yes
C16 m No      Yes
C17 f No      Yes
C18 f Yes ND     No
C19 f Yes      No
C20 f No      Yes
C21 f Yes ND     No
C22 f No      Yes
C23 f No      Yes
C24 f No      Yes
Abbreviations: DPCP, diphenylcyclopropenone; f, female; m, male; ND,
not determined; PAR, primary allergic response; PLE, polymorphic light
eruption; SED, standard erythemal dose.
Table 3. Resensitization with DPCP (40 lg) in
UVR-immunosuppressed (a) PLE patients and
(b) healthy controls
PAR DPCP patch testing dose
Immuno-
tolerance
6.4 lg 3.2 lg 1.6 lg 0.8 lg 0.4 lg
(a) Patient1
P01 f Yes ND ND ND + + No
P04 f Yes ND ND ++ + + No
P05 f Yes      No
P07 m Yes ND ND + +  No
P08 f Yes ND + +   No
P10 f Yes NT NT NT NT NT No
P12 m Yes ND ND ++ ++  No
P14 m Yes ND     No
P15 f Yes ND ND + +  No
P20 f Yes ND ++ +   No
P21 f Yes      No
P22 m No      Yes
P24 f Yes      No
(b) Control1
C02 m Yes ND + + +  No
C06 f No      Yes
C08 f No      Yes
C11 m No      Yes
C15 f Yes ND ND ++ ++ ++ No
C16 m No      Yes
C17 f No      Yes
C20 f Yes ND ND    No
C22 f No      Yes
C23 f Yes ND     No
C24 f Yes ND ND ++ + + No
Abbreviations: DPCP, diphenylcyclopropenone; f, female; m, male; ND,
not determined; NT, not tested; PAR, primary allergic response; PLE,
polymorphic light eruption; SED, standard erythemal dose.
1Numbering of individual patients and control volunteers is the same as in
Table 2a and b.
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doses for erythema in PLE could produce a bias in Langerhans
cell migration, and cytokines released interstitially suggest a
bias toward proinflammatory responses in PLE (Janssens
et al., 2009). Altered neuroendocrine signaling in the skin of
PLE patients may comprise a further component modulating
the tolerogenic potential of Langerhans cells (Mutyambizi
et al., 2009), although experimental depletion of neuropep-
tides has not shown any effect on the immediate PLE
symptoms (Wolf et al., 2009).
Yoshikawa et al. (1990) found increased UVR-induced
immunotolerance to a chemical allergen in skin cancer
patients. On the other hand, Lembo et al. (2008) discovered
that skin cancer prevalence tended to be lower in PLE
patients and confirmed earlier indications that PLE preva-
lence is reduced in skin cancer patients (Wolf et al., 1998).
These observations together suggest that if increased imm-
unotolerance is characteristic of skin cancer (Yoshikawa
et al., 1990) and decreased immunotolerance is characteristic
of PLE (our results), then clinically manifest PLE could
protect from skin cancer (Lembo et al., 2008) by allowing
immunological elimination of UVR-induced mutated cells
(de Gruijl and Rhodes, 2009).
We conclude that the most important immune deviation in
PLE patients is the diminished propensity to UVR-induced
immunotolerance. Even though the studied patient groups
were considerably larger than in earlier PLE immune
reactivity studies, even larger groups (50–100 patients and
controls) should be investigated to obtain a comprehensive
view of immunosuppression and tolerance induction in PLE.
MATERIALS AND METHODS
Human subjects
Twenty-four Caucasian patients (aged 19–57 years in the beginning
of the study) with PLE diagnosed at Turku University Hospital were
recruited to the study. The patients met the PLE criteria of a PLE
Diagnostic and Severity Form prepared by an international working
party (Rhodes et al., 2009). For each patient, a non-relative, healthy
age-matched control volunteer entered the study. All patients and
control subjects gave their written, informed consent. There were
18 females (75%) and 6 males (25%) in the patient group and
16 females (67%) and 8 males (33%) in the control volunteer group.
In addition, 23 healthy volunteers were enrolled for UVR dose-
finding pilot studies. The protocol was approved by the ethical
committee of the Hospital District of Southwest Finland and
followed the Declaration of Helsinki protocols.
Contact sensitization and elicitation
The protocol used for experimental contact sensitization followed
that of Cooper et al. (1992) with slight modifications. The subjects
were sensitized on irradiated buttock skin 3 days after the irradiation
using two petrolatum-backed 7-mm filter disks each soaked in 20 ml
of 1mg of DPCP (Fluka, Buchs, Switzerland) in 1ml of acetone
(makes 20 mg of DPCP in one filter disk). The filter disks were
mounted in 8-mm aluminum Finn chambers (Epitest, Tuusula,
Finland) and taped onto the skin for 48 hours. Thus, the total DPCP
dose used for sensitization was 40 mg, which is a universally
sensitizing dose (data not shown). In the UVR dose-finding pilot
study, 6 of the 23 volunteers were sensitized immediately after the
irradiation with the 6 SED (Table 1). A primary allergic response
(PAR) is an indicator of sensitization and is defined as a spontaneous
flare of contact hypersensitivity (CHS) at the site of sensitization 1–2
weeks after the epicutaneous application of the allergen.
Three weeks after sensitization, patch testing for CHS elicitation
was performed on the unirradiated right upper volar arm using
petrolatum-backed filter disks soaked with 20ml of acetone containing
0.4, 0.8, 1.6, 3.2, and 6.4mg DPCP or acetone only. The disks were
placed in 8-mm Finn Chambers and taped on the skin for 6hours. The
skin reaction was evaluated at 48hours. The highest DPCP concentra-
tion was usually tested only if no PAR on the sensitization site could be
observed. The intensity of the CHS elicitation response was assessed
visually by an experienced skin allergologist using the scoring
recommended by the International Contact Dermatitis Research Group
(, no reaction; þ ?, macular erythema, here judged as an allergic
reaction, because irritant reactions were unlikely to occur; þ ,
erythema with infiltration; þ þ , erythema with infiltration and
papules or vesicles; þ þ þ , bullous reaction).
UVR-induced immunosuppression and immunotolerance
The Philips HP3136 device (Philips, Eindhoven, the Netherlands)
was used as a source of solar-simulating UVR (Snellman et al.,
1995). To study the short-term immunosuppressive effect of UVR,
contact sensitization was induced by applying 40mg DPCP on the
irradiated buttock skin site (5 5cm) 3 days after irradiation as
described above. The irradiations were performed between September
and April when the seasonal solar UVR in Finland is scant. After 3
weeks, the contact allergy patch testing was performed as described
above.
In the preliminary dose-finding experiment to find a UVR
dose that would cause immunosuppression in approximately every
second healthy volunteer, the volunteers were irradiated on a
5 5 cm skin area in the upper buttock with different doses (2 SED in
7 volunteers, 4 SED in 4 volunteers, and 6 SED in 12 volunteers).
One SED is equivalent to 100 Jm2 of erythemally weighted
radiation, as defined by the International Commission on Illumina-
tion (CIE Technical Committee, 1997; Diffey et al., 1997).
To investigate whether the application of DPCP to the
UVR-exposed skin had induced long-term immunotolerance, the
individuals who showed immunosuppression (no contact sensitiza-
tion) in the short-term study were invited to participate in the next
phase of the study after about 1 year. They were subjected to a
second DPCP sensitization and elicitation testing according to the
same protocol as in the first phase, but without UVR exposure.
Statistics
Two-tailed P-values for differences in PAR reactivity between PLE
patients and healthy volunteers were calculated in 2 2 contingency
tables using Fisher’s exact test.
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